PDS Biotechnology Corp

EU6

Company Profile

  • Business description

    PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

  • Contact

    303A College Road
    East PrincetonNJ08540
    USA

    T: +1 800 208-3343

    E: [email protected]

    https://www.pdsbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    21

Stocks News & Analysis

stocks

ASX energy giant remains undervalued

Growth projects could unlock significant value.
stocks

Samsung and SK Hynix lead chip selloff as China competition fears grow

CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.
stocks

Updating our assumed commodity prices and fair values of the two largest Aussie miners

Stronger copper, aluminum and zinc prices offset by iron ore.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,869.0052.50-0.59%
CAC 407,867.9540.320.52%
DAX 4025,317.2257.320.23%
Dow JONES (US)51,613.6356.47-0.11%
FTSE 10010,691.3641.030.39%
HKSE24,314.1731.05-0.13%
NASDAQ26,945.67258.71-0.95%
Nikkei 22567,744.2933.23-0.05%
NZX 50 Index13,760.3910.790.08%
S&P 5007,746.4758.98-0.76%
S&P/ASX 2008,727.9056.00-0.64%
SSE Composite Index3,767.2333.64-0.88%

Market Movers